HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Isoflavone Supplement Hot Flash Reduction Similar To Placebo – JAMA Study

This article was originally published in The Tan Sheet

Executive Summary

Overweight women who took Novogen's isoflavone-containing Promensil or Rimostil supplements experienced a greater reduction in hot flashes than women taking placebo, according to a study published in the July 9 Journal of the American Medical Association

You may also be interested in...

Natrol Sees More Deals In The Future; Looks To Tailor, Balance Portfolio

An exclusive manufacturing and distribution deal with H57 Nutrition for Original South African H57 Hoodia is a feather in Natrol's cap following several acquisitions and licensing deals in the past three weeks

Herb/Drug Interaction Research Could Include Clinical, Behavioral Studies

Future research on herb/drug interactions could range from clinical trials of botanicals to behavioral studies of consumer use patterns, according to speakers at an American Society of Clinical Pharmacology & Therapeutics workshop in Bethesda, Md. July 22-23

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts